Benchmark Payments. 10 3.10 Royalties............................................................. 10 3.11
Benchmark Payments. With respect to [ * ], Merck shall pay to Tularik:
Benchmark Payments. (a) Taisho shall pay Tularik within [ * ] after the occurrence of the following events: [*] up to an aggregate of $3 million.
Benchmark Payments. CUSTOMER shall be required to make the following payments to DYAX upon achievement of the following benchmarks, *************: Benchmark Payment --------- ------- First ************* ************* by CUSTOMER or any of its affiliates or sublicensees for a Licensed Product First ************* ************* by CUSTOMER or any of its affiliates or sublicensees for a Licensed Product First ************* ************* by CUSTOMER or any of its affiliates or sublicensees for a Licensed Product First ************* Licensed ************* Product in the United States or any country in Europe by Customer or any of its affiliates or sublicensees
Benchmark Payments. (The information marked by *** has been omitted by a request for confidential treatment. The omitted portions will be separately filed with the Commission.)
Benchmark Payments. Signature of this Amendment and transfer of rights to any applicable patents and know-how concerning the countries and territories listed under Far East in Attachment under B ** million US$ Transfer of rights to any applicable patents and know-how and approval of Licensed Products with respect to the first of ****** or ****** or ****** ** million US$ Transfer of rights to any applicable patents and know-how and approval of Licensed Products with respect to the second of ****** or ****** or ****** ** million US$ Transfer of rights to any applicable patents and know-how and approval of Licensed Products with respect to the third of ****** or ****** or ****** ** million US$ -------------- ** million US$ Payments for each benchmark shall be due only in case such benchmark is completed.
Benchmark Payments. In addition to the Upfront Payment, Flu-CoV Cash Funding, Funding for Cost Overruns, In-Kind Funding and any other amounts payable by Licensee under this Funding Agreement, Licensee shall make the following benchmark payments (each, a “Benchmark Payment”) to Licensor as set forth below for each Product Candidate on a Product Candidate-by-Product Candidate basis, or each Product on a Product-by-Product basis, as applicable for each Project Field on a Project-Project Field-by-Project-Project Field basis:
Benchmark Payments. 5.2.1 YAMANOUCHI shall make the determination whether or not each of Delivered Samples has a binding affinity not less than 25% of the corresponding original Murine Anti-gpllb/llla Antibody or fragments thereof ("Binding Affinity Requirement") within sixty (60) days after receipt of such Delivered Samples. YAMANOUCHI and PDL agree that binding affinity will be measured by the method of competitive binding set forth in Queen, et al., Proceedings of the National Academy of Sciences, USA, 86, 1030 (1989). YAMANOUCHI agrees to provide PDL with samples of Murine Anti-gpllb/llla Antibody, F(ab')2 and Fab fragments thereof in order for PDL to perform the competitive binding assay. In addition, PDL agrees to perform Scatchard plot analyses of Delivered Samples. If such Delivered Samples meet the Binding Affinity Requirement, YAMANOUGHI shall pay PDL [ ] ("First Benchmark Payment") within thirty (30) days after such determination. If YAMANOUCHI has not determined the binding affinity within sixty (60) days after receipt of last Delivered Sample, then First Benchmark Payment is due ninety (90) days after receipt of last Delivered Sample.
Benchmark Payments. (a) Taisho shall pay Tularik within [ * ] after the occurrence of the following events: [ * ].
Benchmark Payments. [*****] ------------------ ***** REPRESENTS CONFIDENTIAL PORTION WHICH HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SEC. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. [*****]
